Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL72170 | 1.00 | CA2 (0.59) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL3777741 | 1.00 | CA2 (0.59) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL29229502 | 1.00 | CA2 (0.59) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL2986282 | 1.00 | CA2 (0.59) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| Water SCHEMBL1654584 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| Water SCHEMBL21835627 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| Water SCHEMBL1322817 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| Water SCHEMBL21457923 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| Water SCHEMBL21457922 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 | |
| SCHEMBL2854360 | 0.98 | CA2 (0.57) | CA2ALDH1A1SMN1; SMN2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852171-A | Non-azolanet Process for the preparation of tam | 成都科圣原医药科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| EP-3280701-B1 | A METHOD OF CHIRAL RESOLUTION OF THE KEY INTERMEDIATE OF THE SYNTHESIS OF APREMILAST AND ITS USE FOR THE PREPARATION OF PURE APREMILAST | ZENTIVA KS (CZ) | 2019-10-16 | — | — | EP | claimed |
| US-11844786-B2 | Uses of combinations (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in methods of treating movement disorder | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2023-12-19 | — | — | US | disclosed |
| EP-4168390-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021259860-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2021-12-30 | — | — | WO | disclosed |
| EP-3929179-A1 | ANTI-INFLAMMATORY COMPOUNDS AND METHODS FOR THEIR MANUFACTURE | BIOHORM, S.L. (ES) | 2021-12-29 | — | — | EP | disclosed |
| US-11065232-B2 | Dihydrotetrabenazine for the treatment of anxiety and psychoses | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| US-10668052-B2 | Combinations of isomers of dihydrotetrabenazine | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| EP-3606530-A2 | DIHYDROTETRABENAZINE FOR USE IN THE TREATMENT A MOVEMENT DISORDER | Adeptio Pharmaceuticals Limited (GB) | 2020-02-12 | — | — | EP | disclosed |
| US-20200038384-A1 | DIHYDROTETRABENAZINE FOR THE TREATMENT OF ANXIETY AND PSYCHOSES | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2020-02-06 | — | — | US | disclosed |
| CN-110691596-A | Pharmaceutical composition | 阿德普蒂奥制药有限公司 | 2020-01-14 | — | — | CN | disclosed |
| EP-3280701-B1 | A METHOD OF CHIRAL RESOLUTION OF THE KEY INTERMEDIATE OF THE SYNTHESIS OF APREMILAST AND ITS USE FOR THE PREPARATION OF PURE APREMILAST | ZENTIVA KS (CZ) | 2019-10-16 | — | — | EP | disclosed |
| US-20180280359-A1 | PHARMACEUTICAL COMPOSITIONS | ADEPTIO PHARMACEUTICALS LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-20180280361-A1 | PHARMACEUTICAL COMPOSITIONS | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2018-10-04 | — | — | US | disclosed |
| WO-2018178243-A2 | PHARMACEUTICAL COMPOSITIONS | ADEPTIO PHARMACEUTICALS LIMITED (GB) | 2018-10-04 | — | — | WO | disclosed |
| US-7141560-B2 | Alanine 2,6-dialkoxyphenyl ester derivatives as hypnotics | AKZO NOBEL N.V. (NL) | 2006-11-28 | — | — | US | disclosed |
| EP-1373188-B1 | ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS | AKZO NOBEL NV (NL) | 2006-06-07 | — | — | EP | disclosed |
| US-20040059109-A1 | Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics | N.V. ORGANON (NL) | 2004-03-25 | — | — | US | disclosed |
| EP-1373188-A1 | ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS | Akzo Nobel N.V. (NL) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002057218-A1 | ALANINE 2,6-DIALKOXYPHENYL ESTER DERIVATIVES AS HYPNOTICS | AKZO NOBEL N.V. (NL) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280361-A1 | PHARMACEUTICAL COMPOSITIONS | HTR5A, COMT, GRM5 | CA2 2872/4885ALDH1A1 1324/4885SMN1; SMN2 213/4885 |
| US-11844786-B2 | Uses of combinations (+)-α-dihydrotetrabenazine and (−)-α-dihydrotetrabenazine in methods of treating movement disorder | HTT, COMT, NDUFB5 | CA2 2775/4885ALDH1A1 703/4885SMN1; SMN2 142/4885 |
| US-11065232-B2 | Dihydrotetrabenazine for the treatment of anxiety and psychoses | ADRB1, ADRB2, DBH | CA2 3801/4885ALDH1A1 227/4885SMN1; SMN2 1305/4885 |
| US-20180280359-A1 | PHARMACEUTICAL COMPOSITIONS | HTT, CHRNA5, COMT | CA2 3074/4885ALDH1A1 1382/4885SMN1; SMN2 202/4885 |
| US-20040059109-A1 | Alanine 2, 6-dialkoxyphenyl ester derivatives as hypnotics | OPRM1, OPRD1, OPRK1 | CA2 130/4885ALDH1A1 286/4885SMN1; SMN2 794/4885 |
| US-20200038384-A1 | DIHYDROTETRABENAZINE FOR THE TREATMENT OF ANXIETY AND PSYCHOSES | ADRB1, ADRB2, DBH | CA2 3801/4885ALDH1A1 227/4885SMN1; SMN2 1305/4885 |
| US-10668052-B2 | Combinations of isomers of dihydrotetrabenazine | COMT, QDPR, HTT | CA2 3797/4885ALDH1A1 952/4885SMN1; SMN2 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.